Company Profile
Lee's Pharmaceutical Holdings Limited, an investment holding company develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and globally.
It focuses on various disease areas, such as cardiovascular, woman's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates in Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells Nadroparin Calcium injection and Livaracine to treat blood clots and deep vein thrombosis.
Its portfolio also includes Yallaferon for viral infection, Slounase for hemostasis, Socazolimab Injection for Recurrent or metastatic cervical cancer, Treprostinil injection for pulmonary arterial hypertension, fondaparinux sodium injection for deep vein thrombosis, Sodium Phenylbutyrate Granules to treat urea cycle disorders, Apremilast Tablets for Plaque psoriasis, and Azilsartan Tablets for hypertension.
The Licensed-In Products segment offers Sancuso for chemotherapy induced nausea and vomiting. Its portfolio also includes Bredinin to treat Immunosuppression in renal transplantation, Centraxal Plus for acute otitis media with tympanostomy tubes, and Ferplex to treat iron deficiency anemia. This segment also offers Intrarosa for vulvovaginal atrophy.
Its portfolio also includes Adasuve for agitation associated with schizophrenia or bipolar I disorder in adults, Mictonorm for urinary incontinence, Natulan for Stage III and IV Hodgkin's disease, Lutrate for Prostate cancer, Nitric Oxide for Inhalation for Hypoxic respiratory failure associated with pulmonary hypertension, Omacor to treat Omega-3-acid ethyl esters, Zanidip for hypertension, Readyfusor for post-operative pain management, Teglutik to treat Amyotrophic lateral sclerosis, Trittico for insomnia/depression, Dicoflor and VSL#3 for probiotics, and Zingo for topical local analgesics. Founded in 1994, the company is headquartered in Sha Tin, Hong Kong.